← Evidence map

ArticleOncotarget2015

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.

Ijeoma Adaku Umelo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

7 papers cite it

2015

2016

2017

2018

2019

2020

this papercites it

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade. | OpenQuestion